Current approved therapeutic strategies for IPF and LC treatment
4.9 (486) · $ 13.50 · In stock
Idiopathic Pulmonary Fibrosis (IPF) Workup: Laboratory Studies, Imaging Studies, Other Tests
Ivana CASTANIERE, Medical Doctor
Stefania CERRI, Assistant Professor, MD, PhD
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials, BMC Pulmonary Medicine
Up-regulated SPP1 increases the risk from IPF to lung cancer via activating the pro-tumor macrophages - Computational and Structural Biotechnology Journal
Alessandro MARCHIONI Università degli Studi di Modena e Reggio
Pie chart of ILD severity score of chILD in Egyptian patients
Anna SAMARELLI Università degli Studi di Modena e Reggio Emilia
PDF) Idiopathic pulmonary fibrosis and lung cancer: A clinical and pathogenesis update
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
Stefania CERRI, Assistant Professor, MD, PhD
Giorgia GUAITOLI, Resident
